Search research articles
Contact Us
Filters
Showing results (41-50 of 173) with videos related to
Page
of 18
Sort By:
Cytokines, Cellular & Molecular Therapy
|
October 9, 1999
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma
S Barth, B Matthey, M Huhn, et al.
International Journal of Molecular Medicine
|
December 16, 1998
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines
S Barth, M Huhn, W Wels, et al.
Annals of Hematology
|
October 6, 1998
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
M Jensen, U Winkler, O Manzke, et al.
Bone Marrow Transplantation
|
August 10, 2000
Treatment of patients with malignant lymphomas with monoclonal antibodies
H Tesch, A Engert, O Manzke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
The emerging role of immunotoxins in leukemia and lymphoma
U Winkler, S Barth, R Schnell, et al.
Medizinische Klinik (Munich, Germany : 1983)
|
September 25, 1999
[Role of high-dose chemotherapy in hematology and internal medicine/ oncology]
A Engert, A Josting, M Reiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Immunotoxins: is there a clinical value?
C Gottstein, U Winkler, H Bohlen, et al.
Der Pathologe
|
July 6, 2017
[Recovery of paraffin blocks and central archiving : Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma]
M Čavčić, I Oschlies, M Fuchs, et al.
Biotechniques
|
March 10, 2001
Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages
M K Tur, M Huhn, S Sasse, et al.
Leukemia & Lymphoma
|
April 7, 2009
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
A Engert, L Griskevicius, Y Zyuzgin, et al.
Page
of 18
Search research articles
Search
Showing results (41-50 of 173) with videos related to
Sort By:
Page
of 18
Cytokines, Cellular & Molecular Therapy
|
October 9, 1999
CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma
S Barth, B Matthey, M Huhn, et al.
International Journal of Molecular Medicine
|
December 16, 1998
Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines
S Barth, M Huhn, W Wels, et al.
Annals of Hematology
|
October 6, 1998
Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)
M Jensen, U Winkler, O Manzke, et al.
Bone Marrow Transplantation
|
August 10, 2000
Treatment of patients with malignant lymphomas with monoclonal antibodies
H Tesch, A Engert, O Manzke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
The emerging role of immunotoxins in leukemia and lymphoma
U Winkler, S Barth, R Schnell, et al.
Medizinische Klinik (Munich, Germany : 1983)
|
September 25, 1999
[Role of high-dose chemotherapy in hematology and internal medicine/ oncology]
A Engert, A Josting, M Reiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1994
Immunotoxins: is there a clinical value?
C Gottstein, U Winkler, H Bohlen, et al.
Der Pathologe
|
July 6, 2017
[Recovery of paraffin blocks and central archiving : Experiences of the Kiel lymph node registry and the German study group for Hodgkin lymphoma]
M Čavčić, I Oschlies, M Fuchs, et al.
Biotechniques
|
March 10, 2001
Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages
M K Tur, M Huhn, S Sasse, et al.
Leukemia & Lymphoma
|
April 7, 2009
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
A Engert, L Griskevicius, Y Zyuzgin, et al.
Page
of 18